Opaleye Management Inc. Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001595855

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallFocusedHealth TiltHigh Turnover how tags are computed

Q3 2024 · 43 positions · Total reported value $595.37M · Top-10 concentration 73.1% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 50.0% · 13 new · 12 cut · 8 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q1 2026 → Q2 2026): +40.3% · vs SPY +25.5% · Prev Value $739.73M — last quarter positions weighted by this quarter price moves · ranking

In its Q3 2024 13F filing, Opaleye Management Inc. disclosed 43 equity positions with a combined reported value of $595.37M. The filing implies a focused portfolio: its ten largest positions account for 73.1% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q3 2024 were HROW ($179.39M), TGTX ($53.33M), OCUL ($43.72M). By sector, the heaviest allocations are Health Care 86.4%, Industrials 4.5%. Versus the prior quarter, allocation shifted toward Health Care (+2.4pp), Industrials (+2.0pp) and away from Other (-4.4pp).

Versus the prior quarter, Opaleye Management Inc. opened 13 new positions, trimmed 12 and fully exited 8, a turnover rate of 50.0% of positions. The portfolio's overlap with the prior quarter was 67% of names.

The largest new positions opened in Q3 2024 were DNA ($6.68M), ZNTL ($3.56M), RZLT ($2.26M).

Of the 8 positions fully exited versus the prior quarter, the largest were FDMT ($7.26M), IOVA ($7.19M), NTLA ($4.88M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q3 2024)

  • DNA GINKGO BIOWORKS HOLDINGS INC · $6.68M
  • ZNTL ZENTALIS PHARMACEUTICALS INC · $3.56M
  • RZLT REZOLUTE INC · $2.26M
  • PEPG PEPGEN INC · $1.53M
  • RVNC REVANCE THERAPEUTICS INC · $1.43M
  • ADGM ADAGIO MED HLDGS INC · $285.27K

Fully Exited (vs previous quarter)

  • FDMT 4D MOLECULAR THERAPEUTICS IN · prev qtr: $7.26M · history
  • IOVA IOVANCE BIOTHERAPEUTICS INC · prev qtr: $7.19M
  • NTLA Intellia Therapeutics, Inc. · prev qtr: $4.88M · history
  • LXRX LEXICON PHARMACEUTICALS INC · prev qtr: $3.15M
  • SVRA SAVARA INC · prev qtr: $2.88M
  • VTYX VENTYX BIOSCIENCES INC · prev qtr: $2.75M
  • VSTM VERASTEM INC · prev qtr: $2.73M · history
  • FULC FULCRUM THERAPEUTICS INC · prev qtr: $1.77M

Insider Transactions (Form 4)

Latest Opaleye Management Inc. buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

Transaction date Activity Security Shares Price Filing
2026-11-05 Buy Grace Therapeutics, Inc. 3,087 $1.77 SEC filing
2026-11-04 Buy Grace Therapeutics, Inc. 5,027 $1.80 SEC filing
2026-11-03 Buy Grace Therapeutics, Inc. 10,328 $1.79 SEC filing
2026-10-26 Buy Grace Therapeutics, Inc. 66,411 $1.77 SEC filing
2026-10-23 Buy Alpha Cognition Inc. 14,973 $8.23 SEC filing
2026-10-22 Buy Alpha Cognition Inc. 17,117 $8.33 SEC filing
2026-10-22 Buy Grace Therapeutics, Inc. 21,390 $1.93 SEC filing
2026-10-19 Buy Grace Therapeutics, Inc. 4,256 $1.88 SEC filing

All insider transactions →

Fund Profile

Opaleye Management Inc. is an SEC-registered 13F filer based in Boston, MA, United States. As of Q2 2026 it reported 58 US equity positions with a combined value of $1.10B. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Firm Snapshot

  • Headquarters: BOSTON, MA, United States
  • SEC registration: 801-78700 (status: Approved), registered 2013-10-29
  • Regulatory AUM (Form ADV): $802.77M as of 2026-02-19
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 1 private funds, of which 1 hedge funds

Portfolio Structure

  • 58 positions · $1.10B reported value (Q2 2026)
  • Top 10 holdings = 64.8% of reported value
  • Largest position: LQDA (LIQUIDIA CORPORATION) at 17.7%
  • Average position size: $19.04M

Sector Tilt

  • Health Care 90.7%
  • Materials 1.9%
  • Industrials 1.4%
  • (classified holdings cover 94% of value)

Quarterly Activity

  • Q2 2026: 13 new, 14 added, 12 reduced, 8 exited
  • 19 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall Direction and Market View: The fund appears to maintain a cautious approach with a slight inclination towards growth in the healthcare sector. The addition of new positions in healthcare companies suggests an optimism in the sector's potential, while reductions in some holdings indicate selectivity and risk management. 2. Key Moves: - Added: IRON (DISC MEDICINE INC) with a significant increase of 103.1% in shares, MGTX (MeiraGTx Holdings plc) with a 67.2% increase in shares. - Reduced: LQDA (LIQUIDIA CORPORATION) by 3.8% in shares, HROW (HARROW INC) by 15.3% in shares. - Hold: The majority of the top holdings, including ETON (ETON PHARMACEUTICALS INC COM), URGN (UROGEN PHARMA LTD), APGE (APOGEE THERAPEUTICS INC), SLGL (Sol-Gel Technologies Ltd), RZLT (REZOLUTE INC), and TGTX (TG THERAPEUTICS INC). 3. Portfolio Structure: - Passive/Active: The rebalancing appears more active, with strategic additions and reductions. - Sector Bias: The healthcare sector is the clear bias, with 10 out of 11 top holdings in healthcare. - Risk Appetite: The fund exhibits a moderate risk appetite, with significant additions to high-growth potential companies but also reductions in certain positions. 4. Per-Holding One-Liner: - LQDA (LIQUIDIA CORPORATION): Develops and commercializes innovative therapies for serious diseases. - ETON (ETON PHARMACEUTICALS INC COM): Focuses on the development of treatments for central nervous system disorders. - HROW (HARROW INC): A biopharmaceutical company focused on the development of treatments for cancer. - IRON (DISC MEDICINE INC): Engages in the research and development of therapies for rare and orphan diseases. - URGN (UROGEN PHARMA LTD): Specializes in the development of therapies for urological conditions. - APGE (APOGEE THERAPEUTICS INC): Focuses on the development of therapies for cancer and other diseases. - MGTX (MeiraGTx Holdings plc): Develops treatments for a range of ophthalmic diseases. - SLGL (Sol-Gel Technologies Ltd): Engages in the development and production of advanced materials and technologies. - RZLT (REZOLUTE INC): Specializes in the development of treatments for rare diseases. - TGTX (TG THERAPEUTICS INC): Focuses on the development of therapies for cancer and other diseases. - Unverified: No unverified holdings noted. 5. One-Sentence Style Summary: The fund maintained a selective approach in healthcare, focusing on growth potential with strategic additions and reductions, while maintaining a cautious stance through sector concentration and selective adjustments.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice.

Sector Allocation

Health Care 86.4%
Other 9.1%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 3.99M $179.39M 30.13%
30.13%
Hold
2 2.28M $53.33M 8.96%
8.96%
Hold
3 5.03M $43.72M 7.34%
7.34%
Reduce
4 1.25M $30.91M 5.19%
5.19%
Add
5 8.77M $27.01M 4.54%
4.54%
Add
6 500.00K $26.20M 4.40%
4.40%
Reduce
7 395.28K $22.95M 3.85%
3.85%
Add
8 1.24M $18.09M 3.04%
3.04%
Add
9 1.70M $16.98M 2.85%
2.85%
Add
10 2.78M $16.68M 2.80%
2.80%
Add
11 522.50K $13.95M 2.34%
2.34%
Reduce
12 541.44K $11.83M 1.99%
1.99%
Reduce
13 1.32M $11.22M 1.89%
1.89%
Reduce
14 85.00K $9.71M 1.63%
1.63%
Hold
15 420.00K $9.44M 1.58%
1.58%
Hold
16 1.89M $9.34M 1.57%
1.57%
Add
17 2.57M $8.58M 1.44%
1.44%
Reduce
18 3.81M $6.97M 1.17%
1.17%
Reduce
19 820.20K $6.68M 1.12%
1.12%
New
20 353.50K $6.65M 1.12%
1.12%
Reduce
21 250.00K $6.62M 1.11%
1.11%
Hold
22 64.00K $6.55M 1.10%
1.10%
Add
23 335.00K $5.56M 0.93%
0.93%
Add
24 404.10K $5.13M 0.86%
0.86%
Reduce
25 105.00K $4.72M 0.79%
0.79%
Hold
26 75.30K $3.98M 0.67%
0.67%
Reduce
27 6.00M $3.96M 0.67%
0.67%
Add
28 3.67M $3.71M 0.62%
0.62%
Reduce
29 967.00K $3.56M 0.60%
0.60%
New
30 1.68M $3.08M 0.52%
0.52%
Reduce
31 466.56K $2.26M 0.38%
0.38%
New
32 112.50K $2.24M 0.38%
0.38%
Reduce
33 800.00K $2.08M 0.35%
0.35%
Add
34 1.40M $1.93M 0.32%
0.32%
Reduce
35 2.41M $1.57M 0.26%
0.26%
Reduce
36 480.00K $1.56M 0.26%
0.26%
Reduce
37 179.20K $1.53M 0.26%
0.26%
New
38 275.00K $1.43M 0.24%
0.24%
New
39 654.94K $1.41M 0.24%
0.24%
Reduce
40 440.00K $919.60K 0.15%
0.15%
Hold
41 535.00K $839.95K 0.14%
0.14%
Reduce
42 375.00K $832.50K 0.14%
0.14%
Hold
43 110.57K $285.27K 0.05%
0.05%
New

FAQ

What did Opaleye Management Inc. buy in 2024-Q3?

In its 2024-Q3 13F filing, Opaleye Management Inc. reported 43 equity positions worth $595.37M in aggregate; its largest disclosed positions were HROW ($179.39M), TGTX ($53.33M), OCUL ($43.72M).

How large is Opaleye Management Inc.'s portfolio?

Opaleye Management Inc. reported $595.37M of long equity holdings across 43 positions as of 2024-Q3. Top-10 holdings account for 73.1% of reported value.

What is Opaleye Management Inc.'s investment style?

HoldingsHub classifies the portfolio as Small / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/opaleye-management/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →